Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

NETSPOT Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

When do Netspot patents expire, and what generic alternatives are available?

Netspot is a drug marketed by Aaa Usa Inc and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-six patent family members in nineteen countries.

The generic ingredient in NETSPOT is gallium dotatate ga-68. There are sixteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the gallium dotatate ga-68 profile page.

US ANDA Litigation and Generic Entry Outlook for Netspot

  Start Trial

Netspot will be eligible for patent challenges on June 1st, 2020. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be August 10th, 2032. This may change due to patent challenges or generic licensing.

Summary for NETSPOT
International Patents:26
US Patents:1
Suppliers / Packagers: 1
Clinical Trials: 4
DailyMed Link:NETSPOT at DailyMed
Drug patent expirations by year for NETSPOT
Generic Entry Opportunity Date for NETSPOT
Generic Entry Date for NETSPOT*:
Constraining patent/regulatory exclusivity:

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for NETSPOT

Identify potential brand extensions & 505(b)(2) entrants

Assistance Publique - Hôpitaux de ParisPhase 3
University of Alabama at BirminghamEarly Phase 1
West Virginia UniversityPhase 2

See all NETSPOT clinical trials

US Patents and Regulatory Information for NETSPOT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Aaa Usa Inc NETSPOT gallium dotatate ga-68 POWDER;INTRAVENOUS 208547-001 Jun 1, 2016 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Aaa Usa Inc NETSPOT gallium dotatate ga-68 POWDER;INTRAVENOUS 208547-001 Jun 1, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
Aaa Usa Inc NETSPOT gallium dotatate ga-68 POWDER;INTRAVENOUS 208547-001 Jun 1, 2016 RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.